Clinic
Providence Hospital
Providence Hospital was paid $12.18M by Medicaid between Jan 2018 and Apr 2019, across 303 billing codes. Its largest line is 99284, emergency room visit (serious) — 13% of everything it billed.
33Billing provider infoPROVIDENCE HOSPITAL
WASHINGTON, DC 20017
WASHINGTON, DC 20017
33aNPI1932190626assigned 11/02/2005
33bProvider typeUrgent Care Clinic/Center
28Total paid$12.18M
24GClaims242,422
24DCodes billed303
24AFirst – last monthJan 2018 – Apr 2019
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 227,303 | $11.44M | |
| 2019 | 15,119 | $738K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 9,980 | 9,020 | $1.53M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.5% | 6,493 | 5,801 | $1.04M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 8.3% | 6,243 | 1,846 | $1.01M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.1% | 4,272 | 3,855 | $622K |
| 97010 | 4.7% | 1,602 | 639 | $567K | |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3.4% | 3,417 | 2,812 | $414K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.3% | 2,967 | 2,549 | $404K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 3.3% | 551 | 482 | $403K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.1% | 952 | 863 | $383K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.9% | 2,885 | 2,255 | $351K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 2.4% | 1,913 | 1,377 | $294K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.2% | 950 | 880 | $270K |
291 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.1% | 1,372 | $257K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.1% | 1,322 | $253K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.8% | 9,838 | $216K |
| 97014 | 1.8% | 1,026 | $214K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.5% | 274 | $186K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.4% | 290 | $165K |
| 95811 | 1.3% | 239 | $157K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 497 | $143K |
| G0378 | Hospital observation service, per hour | 1.1% | 1,399 | $137K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 1.1% | 318 | $137K |
| 94660 | 1.1% | 259 | $131K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 674 | $121K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 846 | $105K |
| 97162 | <1% | 752 | $95K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,591 | $94K |
| 76642 | <1% | 697 | $94K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,922 | $90K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 358 | $88K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 866 | $79K |
| 20610 | <1% | 672 | $78K | |
| 76801 | <1% | 565 | $75K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 555 | $74K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 257 | $71K |
| 76830 | Ultrasound, transvaginal | <1% | 511 | $70K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 720 | $68K |
| 93971 | <1% | 455 | $60K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 168 | $59K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 450 | $58K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,892 | $56K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 313 | $54K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 269 | $53K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 258 | $52K |
| 97163 | <1% | 275 | $43K | |
| G0424 | Pulmonary rehabilitation, including exercise (includes monitoring), one hour, per session, up to two sessions per day | <1% | 1,213 | $41K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 320 | $33K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 78 | $32K |
| 97035 | <1% | 328 | $29K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 103 | $29K |
| 73630 | <1% | 1,114 | $28K | |
| 84484 | <1% | 2,885 | $28K | |
| 92551 | <1% | 353 | $26K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 301 | $24K |
| 71250 | <1% | 272 | $24K | |
| J2357 | Injection, omalizumab, 5 mg | <1% | 72 | $24K |
| 76770 | <1% | 238 | $24K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 221 | $23K |
| 97116 | <1% | 219 | $22K | |
| 80076 | <1% | 4,589 | $22K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,032 | $22K |
| 93970 | <1% | 215 | $21K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 165 | $21K |
| 97164 | <1% | 540 | $20K | |
| 72141 | <1% | 109 | $20K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 11,247 | $20K |
| 73562 | <1% | 1,200 | $20K | |
| 76536 | <1% | 140 | $19K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 627 | $18K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 984 | $18K |
| 77080 | <1% | 426 | $17K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 89 | $16K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 252 | $16K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,341 | $16K |
| 36430 | <1% | 62 | $15K | |
| 72110 | <1% | 396 | $15K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,609 | $15K |
| 99173 | <1% | 384 | $15K | |
| 80053 | Comprehensive metabolic panel | <1% | 2,115 | $14K |
| J0897 | Injection, denosumab, 1 mg | <1% | 43 | $14K |
| 73030 | <1% | 641 | $13K | |
| 77062 | <1% | 280 | $13K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,803 | $12K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 22 | $12K |
| 97012 | <1% | 37 | $12K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,374 | $12K |
| 97161 | <1% | 203 | $11K | |
| 99408 | <1% | 87 | $11K | |
| 90714 | <1% | 421 | $11K | |
| 74183 | <1% | 27 | $11K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 84 | $11K |
| 76641 | <1% | 69 | $10K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 100 | $10K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,885 | $9K |
| 73221 | <1% | 59 | $9K | |
| 83880 | <1% | 807 | $9K | |
| 86803 | <1% | 1,383 | $9K | |
| 70486 | <1% | 193 | $9K | |
| 87040 | <1% | 525 | $9K | |
| 73610 | <1% | 593 | $8K | |
| 73130 | <1% | 559 | $8K | |
| 80320 | <1% | 570 | $8K | |
| 85576 | <1% | 625 | $8K | |
| 97165 | <1% | 30 | $7K | |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | <1% | 124 | $7K |
| 84100 | <1% | 1,540 | $7K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 160 | $7K |
| 73502 | <1% | 391 | $7K | |
| 97166 | <1% | 22 | $7K | |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 40 | $6K |
| 72050 | <1% | 175 | $6K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 126 | $6K |
| 94010 | <1% | 1,171 | $6K | |
| 83605 | <1% | 683 | $6K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,107 | $6K |
| 83690 | <1% | 2,139 | $5K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,987 | $5K |
| 83735 | <1% | 2,140 | $5K | |
| 86703 | <1% | 1,302 | $5K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 411 | $5K |
| 84146 | <1% | 376 | $5K | |
| 77066 | Tomosynthesis, mammo | <1% | 397 | $5K |
| 82962 | <1% | 7,158 | $5K | |
| 73110 | <1% | 270 | $4K | |
| 84702 | <1% | 630 | $4K | |
| 29125 | <1% | 13 | $4K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 113 | $4K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 30 | $4K |
| 12001 | <1% | 14 | $4K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,183 | $4K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,154 | $4K |
| 85379 | <1% | 362 | $4K | |
| 86901 | <1% | 524 | $4K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 130 | $4K |
| 76870 | <1% | 30 | $3K | |
| V2632 | Posterior chamber intraocular lens | <1% | 588 | $3K |
| 72100 | <1% | 272 | $3K | |
| 99234 | <1% | 521 | $3K | |
| 72197 | <1% | 13 | $3K | |
| 72070 | <1% | 90 | $3K | |
| 81001 | <1% | 2,541 | $3K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 635 | $3K |
| 80164 | <1% | 263 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,078 | $3K |
| 81025 | <1% | 5,377 | $2K | |
| 86480 | <1% | 212 | $2K | |
| 73560 | <1% | 101 | $2K | |
| 73565 | <1% | 116 | $2K | |
| 74018 | <1% | 110 | $2K | |
| 90686 | <1% | 263 | $2K | |
| 73080 | <1% | 105 | $2K | |
| 90715 | <1% | 106 | $2K | |
| 80061 | Lipid panel | <1% | 561 | $2K |
| 86850 | <1% | 514 | $2K | |
| 90656 | <1% | 276 | $2K | |
| 72040 | <1% | 113 | $2K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 15 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,583 | $2K |
| C1769 | Guide wire | <1% | 320 | $2K |
| 70544 | <1% | 13 | $2K | |
| 86900 | <1% | 515 | $1K | |
| 87081 | <1% | 692 | $1K | |
| 73590 | <1% | 121 | $1K | |
| 81002 | <1% | 3,641 | $1K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 529 | $1K |
| 87522 | Neg quan hep c or qual rna | <1% | 43 | $1K |
| 82248 | <1% | 239 | $1K | |
| 90732 | <1% | 86 | $1K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 531 | $1K |
| 80177 | <1% | 155 | $1K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 385 | $1K |
| 76857 | <1% | 12 | $997.50 | |
| 80156 | <1% | 96 | $977.32 | |
| 86592 | <1% | 270 | $970.60 | |
| 84153 | <1% | 387 | $960.75 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 890 | $958.94 |
| 86706 | <1% | 404 | $949.93 | |
| 82607 | <1% | 204 | $943.75 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,167 | $931.40 |
| 90674 | <1% | 146 | $854.18 | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 16 | $838.70 |
| 87340 | <1% | 355 | $787.97 | |
| 73522 | <1% | 40 | $778.75 | |
| 80185 | <1% | 66 | $693.46 | |
| 73090 | <1% | 40 | $662.36 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 533 | $658.11 |
| 88304 | <1% | 169 | $654.97 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,964 | $653.85 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,297 | $633.77 |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 28 | $631.05 |
| 90670 | <1% | 18 | $613.75 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 980 | $610.74 |
| 74022 | <1% | 46 | $572.37 | |
| 85610 | <1% | 893 | $563.95 | |
| A9270 | Non-covered item or service | <1% | 8,141 | $510.44 |
| 84439 | <1% | 130 | $484.80 | |
| 73564 | <1% | 52 | $469.27 | |
| 87205 | <1% | 163 | $451.80 | |
| 85730 | <1% | 791 | $450.45 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 20 | $447.91 |
| 85027 | <1% | 227 | $447.40 | |
| 87088 | <1% | 393 | $402.52 | |
| 84295 | <1% | 154 | $399.05 | |
| 87070 | <1% | 149 | $389.77 | |
| 82746 | <1% | 120 | $341.40 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 148 | $329.11 |
| 99406 | <1% | 17 | $315.36 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 834 | $296.10 |
| 99152 | <1% | 114 | $293.78 | |
| 88312 | <1% | 295 | $279.13 | |
| 82550 | <1% | 239 | $275.05 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 804 | $273.76 |
| 85014 | <1% | 239 | $271.61 | |
| 90658 | <1% | 21 | $266.61 | |
| 96376 | <1% | 508 | $262.36 | |
| 82150 | <1% | 210 | $261.41 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 122 | $238.63 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 396 | $215.70 |
| 88313 | <1% | 315 | $207.77 | |
| 86140 | <1% | 247 | $206.01 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,785 | $204.05 |
| 80184 | <1% | 27 | $202.04 | |
| 82565 | <1% | 356 | $201.92 | |
| 87186 | <1% | 165 | $197.89 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 469 | $185.72 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,173 | $185.62 |
| 85651 | <1% | 302 | $182.19 | |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 283 | $179.61 |
| 83540 | <1% | 108 | $178.95 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,687 | $177.91 |
| 86709 | <1% | 132 | $166.31 | |
| 82728 | <1% | 44 | $160.07 | |
| 92557 | <1% | 12 | $152.14 | |
| 82570 | <1% | 51 | $144.11 | |
| 94760 | <1% | 530 | $142.07 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,049 | $116.40 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 526 | $102.48 |
| 82010 | <1% | 279 | $101.81 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 61 | $99.41 |
| 96402 | <1% | 36 | $94.00 | |
| 86705 | <1% | 45 | $89.27 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 878 | $79.51 |
| 86920 | <1% | 114 | $76.83 | |
| 84550 | <1% | 97 | $76.78 | |
| 83550 | <1% | 81 | $69.07 | |
| 81000 | <1% | 236 | $67.69 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 620 | $65.86 |
| 86735 | <1% | 16 | $65.64 | |
| 84132 | <1% | 179 | $57.53 | |
| 86787 | <1% | 28 | $54.67 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 157 | $53.38 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,031 | $52.81 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 529 | $51.28 |
| 82140 | <1% | 13 | $51.24 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 119 | $50.19 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 394 | $50.05 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 680 | $49.30 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 450 | $48.91 |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 14 | $46.22 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 77 | $43.44 |
| J1815 | Injection, insulin, per 5 units | <1% | 500 | $40.48 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 148 | $37.61 |
| C1729 | Catheter, drainage | <1% | 27 | $34.78 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 93 | $28.17 |
| 82803 | <1% | 82 | $25.62 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 190 | $24.18 |
| 85044 | <1% | 53 | $22.34 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 256 | $21.89 |
| 85018 | <1% | 133 | $18.63 | |
| 82043 | <1% | 17 | $14.43 | |
| 80069 | <1% | 13 | $13.47 | |
| 82465 | <1% | 15 | $11.28 | |
| 86580 | <1% | 16 | $10.94 | |
| 86765 | <1% | 13 | $10.92 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 220 | $9.88 |
| 86708 | <1% | 13 | $9.60 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 360 | $9.50 |
| 88342 | <1% | 18 | $8.95 | |
| 88341 | <1% | 16 | $8.95 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 68 | $7.06 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 318 | $4.94 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 111 | $4.75 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 74 | $4.04 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 55 | $3.38 |
| 36600 | <1% | 13 | $3.14 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 37 | $2.47 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 56 | $2.37 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 374 | $0.02 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 491 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 89 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 75 | $0.00 |
| 96367 | 0% | 29 | $0.00 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 23 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 47 | $0.00 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 15 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 13 | $0.00 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 12 | $0.00 |
| 69210 | 0% | 17 | $0.00 | |
| 71101 | 0% | 13 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 64 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 87 | $0.00 |
| 96368 | 0% | 32 | $0.00 | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFURNISS, SCOTT (SR. VP FINANCE/CFO)
| Provider | Location | Paid |
|---|---|---|
| Providence Hospital | Washington, DC | $1.37M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.